ReviewBiological psychiatry2007
Early pharmacological treatment of autism: a rationale for developmental treatment.
Review in Biological psychiatry, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 51 citations in OpenAlex.
- Trial
- UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder.The pharmacogenomics journal · 2018Observational
- Behavioral training reverses global cortical network dysfunction induced by perinatal antidepressant exposure.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Preliminary efficacy of adapted responsive teaching for infants at risk of autism spectrum disorder in a community sample.Autism research and treatment · 2015Article
- The microbiome: stress, health and disease.Mammalian genome : official journal of the International Mammalian Genome Society · 2014Review
- A review of the serotonin transporter and prenatal cortisol in the development of autism spectrum disorders.Molecular autism · 2013Article
- Sociability and brain development in BALB/cJ and C57BL/6J mice.Behavioural brain research · 2012Article
- Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart review.Autism research and treatment · 2012Article
- [Psychopharmacology of autism spectrum disorders].Der Nervenarzt · 2011Review
- Brain derived neurotrophic factor and serotonin transporter binding as markers of clinical response to fluoxetine therapy in children with autism.Journal of pediatric neurology : JPN · 2011Article
- Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder.European child & adolescent psychiatry · 2010Review
- Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010Article
- Evolution in health and medicine Sackler colloquium: Comparative genomics of autism and schizophrenia.Proceedings of the National Academy of Sciences of the United States of America · 2010Review
- Neurodevelopmental disorders: cluster 2 of the proposed meta-structure for DSM-V and ICD-11.Psychological medicine · 2009Review
- The serotonergic system: its role in pathogenesis and early developmental treatment of autism.Current neuropharmacology · 2009Article
- Enhanced long-term microcircuit plasticity in the valproic Acid animal model of autism.Frontiers in synaptic neuroscience · 2009Article
- What's new in autism?European journal of pediatrics · 2008Review
- Perceptual metrics of individuals with autism provide evidence for disinhibition.Autism research : official journal of the International Society for Autism Research · 2008Article
- Vibrotactile adaptation fails to enhance spatial localization in adults with autism.Brain research · 2007Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Autism is a dynamic neurodevelopmental syndrome in which disabilities emerge during the first three postnatal years and continue to evolve with ongoing development. We briefly review research in autism describing subtle changes in molecules important in brain development and neurotransmission, in morphology of specific neurons, brain connections, and in brain size. We then provide a general schema of how these processes may interact with particular emphasis on neurotransmission. In this context, we present a rationale for utilizing pharmacologic treatments aimed at modifying key neurodevelopmental processes in young children with autism. Early treatment with selective serotonin reuptake inhibitors (SSRIs) is presented as a model for pharmacologic interventions because there is evidence in autistic children for reduced brain serotonin synthesis during periods of peak synaptogenesis; serotonin is known to enhance synapse refinement; and exploratory studies with these agents in autistic children exist. Additional hypothetical developmental interventions and relevant published clinical data are described. Finally, we discuss the importance of exploring early pharmacologic interventions within multiple experimental settings in order to develop effective treatments as quickly as possible while minimizing risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.